Skip to main content
 

X

News

BeiGene News

See all News

  • September 17, 2020
    BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

    BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

  • September 10, 2020
    BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

    BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

  • September 9, 2020
    BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

    BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

  • September 4, 2020
    BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

    BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

  • August 27, 2020
    BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

    BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

  • August 25, 2020
    BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors

    BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors

  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160
    Listings
  • 6Internally Developed
    Clinical Candidates
  • 5Marketed
    Products
    in China
  • 1Approved
    products
    in the U.S.
  • 4200+Global Team
story
 
  • 2010

    • BeiGene was founded as a research and development company
    BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.
  • 2012

    • Began work on an anti-PD-1 antibody and a BTK inhibitor
    Immuno-oncology Therapies
  • 2014

    • Started clinical trials of pamiparib and zanubrutinib
    Clinical Researcher
  • 2016

    • Went public on the Nasdaq, with $182 million initial public offering
    First China biotech to go public on the Nasdaq
  • 2018

    • Established first European office in Switzerland
    • 50+ ongoing or planned clinical trials
    BeiGene expands global operations
  • 2019

    • Received first FDA approval for BRUKINSA™ (zanubrutinib)
    • Received first approval for tislelizumab in China
    2019

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeattleAmbrx LogoMirati LogoMEI logoAmgen logoEUSA LogoAssembly Bio LogoChi-Med LogoBio-Thera LogoSinglomics Logo

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers